Managing Dogs with Chronic Atopic Dermatitis

Compendium on Continuing Education for the Practicing Veterinarian

Volumn 23, Issue 5, 2001, Pages 454-460

  Marsella, Rosanna ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0347666023     PISSN: 01931903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Halliwell RE: Atopic disease in the dog. Vet Rec 89(8):209-214, 1971.
2. Magnan A, Mely L, Prato S, et al: Relationships between natural T cells, atopy, IgE levels, and IL-4 production. Allergy 55(3):286-290, 2000.
3. Yssel H, Groux H: Characterization of T cell subpopulations involved in the pathogenesis of asthma and allergic diseases. Int Arch Allergy Immunol 121(1):10-18, 2000.
4. Olivry T, Dean GA, Tompkins MB, et al: Toward a canine model of atopic dermatitis: Amplification of cytokine-gene transcripts in the skin of atopic dogs. Exp Dermatol 8(3): 204-211, 1999.
5. Olivry T, Moore PF, Affolter VK, Naydan DK: Langerhans' cell hyperplasia and IgE expression in canine atopic dermatitis. Arch Dermatol Res 288(10):579-585, 1996.
6. Rosser EJ: Advances in the diagnosis and treatment of atopy. Vet Clin North Am Small Anim Pract 29(6):1437-1447, 1999.
7. Hill PB, Moriello KA, DeBoer DJ: Concentrations of total serum IgE, IgA, and IgG in atopic and parasitized dogs. Vet Immunol Immunopathol 44(2):105-113, 1995.
8. Gupta MA, Gupta AK, Schork NJ, Ellis CN: Depression modulates pruritus perception: A study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosom Med 56(1):36-40, 1994.
9. Bevier DE: Long-term management of atopic disease in the dog. Vet Clin North Am Small Anim Pract 20(6):1487-1507, 1990.
10. Stewart LJ: The role of pyoderma in pruritus. Vet Clin North Am Small Anim Pract 18(5):1013-1022, 1988.
11. Scott DW, Miller WH, Griffin CE: Small Animal Dermatology, ed 6. Philadelphia, WB Saunders Co, 2001, pp 583-601.
12. Codner EC, Lessard P: Comparison of intradermal allergy test and enzyme-linked immunosorbent assay in dogs with allergic skin disease. JAVMA 202(5):739-743, 1993.
13. Peng Z, Arthur G, Rector ES, et al: Heterogeneity of polyclonal IgE characterized by differential charge, affinity to protein A, and antigenicity. Allergy Clin Immunol 100(1): 87-95, 1997.
14. Harvey RG: A blinded, placebo-controlled study of the efficacy of borage seed oil and fish oil in the management of canine atopy. Vet Rec 144(15):405-407, 1999.
15. Scott DW, Miller Jr WH: Nonsteroidal management of canine pruritus: Chlorpheniramine and a fatty acid supplement (DVM Derm Caps) in combination, and the fatty acid supplement at twice the manufacturer's recommended dosage. Cornell Vet 80(4):381-387, 1990.
16. Yaqoob P, Calder P: Effects of dietary lipid manipulation upon inflammatory mediator production by murine macrophages. Cell Immunol 163:120-128, 1995.
17. Campbell KL, Uhland CF, Dorn GP: Effects of sunflower oil on serum and cutaneous fatty acid concentration profiles in seborrheic dogs. Vet Dermatol 3(1):29-35, 1992.
18. Paterson S: Additive benefits of EFAs in dogs with atopic dermatitis after partial response to antihistamine therapy. J Small Anim Pract 36(9):389-394, 1995.
19. Bond R, Lloyd DH, Craig MJ: The effects of essential fatty acid supplementation on intradermal skin test reactivity in atopic dogs: A preliminary study. Vet Dermatol 4(4):191-197, 1993.
20. Ho S, Clipstone N, Timmermann L, et al: The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 80(3 pt 2):40-45, 1996.
21. Sowden JM, Berth-Jones J, Ross JS, et al: Double-blind, controlled, cross-over study of cyclosporine in adults with severe refractory atopic dermatitis. Lancet 338:137-140, 1991.
22. Fontaine J: Use of cyclosporine for the management of atopic dermatitis in the dog: A pilot trial. Proc 16th Annu Meet ESVD/ECVD: 137, 1999.
23. Olivry T, Rivierre C, Jackson HA, Murphy KM: Cyclosporin A decreases skin lesions and pruritus in dogs with atopic dermatitis: a prednisolone controlled blinded trial. Vet Dermatol 11(Suppl 1):47, 2000.
24. Rosenkrantz W: Immunomodulating drugs in dermatology, in Kirk RW (ed): Current Veterinary Therapy X. Philadelphia, WB Saunders Co, 1989, pp 570-577.
25. Chueh SC, Kahan BD: Pretransplant test-dose pharmacokinetic profiles: Cyclosporine microemulsion versus corn oil-based soft gel capsule formulation. J Am Soc Nephrol 9(2): 297-304, 1998.
26. Ritschel WA: Microemulsion technology in the reformulation of cyclosporine: The reason behind the pharmacokinetic properties of Neoral. Clin Transplant 10(4):364-373, 1996.
27. Moore JR: Misoprostol and nonsteroidal anti-inflammatory drugs. Ann Int Med 123(4):309-310, 1995.
28. Smith WG, Thompson JM, Kowalski DL: Inhaled misoprostol blocks guinea pig antigen-induced bronchoconstriction and airway inflammation. Am J Resp Crit Care Med 154(2 pt 1):295-299, 1996.
29. Olivry T, Guaguere E, Heriret D: Treatment of atopic dermatitis with misoprostol, a prostaglanding E-1 analogue-an open study. J Dermatol Treat 8:243-247, 1997.
30. Olivry T, Rivierre, C, Jackson HA, et al: A placebo-controlled, blinded trial of misoprostol therapy for canine atopic dermatitis: Effects on dermal cellularity and cutaneous tumor necrosis factor alpha gene transcription. Vet Dermatol 11(Suppl 1):47, 2000.
31. Chan SC, Hanifin JM, Holden CA, et al: Elevated leukocyte phosphodiesterase as a basis for depressed cyclic adenosine monophosphate responses in the Basenji greyhound dog model of asthma. J Allergy Clin Immunol 76(2 pt 1):148-158, 1985.
32. Ferrer L, Alberola J, Queralt M, et al: Clinical anti-inflammatory efficacy of arofylline, a new selective phosphodiesterdase-4 inhibitor, in dogs with atopic dermatitis. Vet Rec 145:191-194, 1999.
33. Neuner P, Klosner G, Schauer E, et al: Pentoxifylline in vivo down-regulates the release of IL-1, IL-6, IL-8 and TNF-alpha by human peripheral blood mononuclear cells. Immunology 83(2):262-267, 1994.
34. Marsella R, Nicklin CF: Double blinded placebo controlled cross over study on the effects of pentoxifylline in canine atopy. Vet Dermatol 11:255-260, 2000.
35. Marsella R, Nicklin CF, Munson J, Roberts SM: Pharmacokinetics of pentoxifylline in dogs after oral and intravenous administration. Am J Vet Res 61(6):631-637, 2000.
36. Ruzicka T: Leukotrienes in atopic eczema. Acta Derm Venereol Suppl (Stockh) 144:48-49, 1989.
37. Spector SL, Smith LJ, Glass M: Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Resp Crit Care Med 150:618-623, 1994.
38. DeBȯer DJ, Moriello KA, Pollet RA: Inability of a short duration treatment with a lipoxygenase inhibitor to reduce clinical signs of canine atopy. Vet Dermatol 5(1): 13-16, 1994.
39. Bell RL, Young PR, Albert D, et al: Discovery and development of zileuton: An orally active 5-lipoxygenase inhibitor. J Immunopharmacol 14(3):505-510, 1992.
40. Woodmansee DP, Simon RA: A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol 83:548-552, 1999.
41. Liu MC, Dube LM, Lancaster J: Acute and chronic effects of a 5-LO inhibitor in asthma: A 6-month randomized multicenter trial: Zileuton study group. J Allergy Clin Immunol 98(5 pt 1):859-871, 1996.
42. Crow D, Marsella R, Nicklin CF: Double blinded pilot study on the efficacy of Zileuton for canine atopic dermatitis. Vet Dermatol 11(Suppl 1):54, 2000.
43. Thomas RC, Logas D, Radosta L, Harrison J: Effects of 1% hydrocortisone conditioner on haematological and biochemical parameters, adrenal function testing and cutaneous reactivity to histamine in normal and pruritic dogs. Vet Dermatol 10:109-116, 1999.